Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 113)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Octreotide |
Approved, Investigational |
Phase 3 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
2 |
|
Cemiplimab |
Approved, Investigational |
Phase 3 |
|
1801342-60-8 |
|
Synonyms:
CEMIPLIMAB
CEMIPLIMAB-RWLC
cemiplimab-rwlc|Libtayo®|REGN-2810|REGN2810|SAR-439684|SAR439684
|
LIBTAYO
REGN2810
REGN-2810
|
|
3 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
4 |
|
Ipilimumab |
Approved |
Phase 3 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
5 |
|
Calcium polycarbophil |
Approved |
Phase 3 |
|
126040-58-2 |
|
Synonyms:
Calcium polycarbophil
Polycarbophil calcium
|
|
|
6 |
|
Imiquimod |
Approved, Investigational |
Phase 3 |
|
99011-02-6 |
57469 |
Synonyms:
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Aldara
Aldara®|R837|S-26308|Zyclara®
Imiquimod
Imiquimod acetate
|
Imiquimodum
R 837
R-837
S-26308
ZARTRA
Zyclara
|
|
7 |
|
Capecitabine |
Approved, Investigational |
Phase 3 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
8 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
9 |
|
Cisplatin |
Approved |
Phase 2, Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
10 |
|
Fluorouracil |
Approved |
Phase 2, Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
11 |
|
Mitomycin |
Approved |
Phase 2, Phase 3 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
12 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
13 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
14 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
15 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
16 |
|
Psyllium |
|
Phase 3 |
|
|
|
17 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
18 |
|
Immune Checkpoint Inhibitors |
|
Phase 3 |
|
|
|
19 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
20 |
|
interferons |
|
Phase 3 |
|
|
|
21 |
|
Anesthetics |
|
Phase 3 |
|
|
|
22 |
|
Vaccines |
|
Phase 3 |
|
|
|
23 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
24 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
25 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
26 |
|
Antimetabolites |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Formaldehyde |
Approved, Vet_approved |
Phase 2 |
|
50-00-0 |
712 |
Synonyms:
Aldeide formica
Fannoform
Formaldehído
Formaldehyd
Formaldehyde
Formaldehyde solution
FORMALIN
Formalina
Formaline
Formalith
Formic aldehyde
|
Formol
Hyperband
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
|
|
30 |
|
Cidofovir |
Approved |
Phase 2 |
|
113852-37-2 |
60613 |
Synonyms:
({[(S)-1-(4-AMINO-2-OXO-1,2-DIHYDROPYRIMIDIN-1-YL)-3-HYDROXYPROPAN-2-YL]OXY}METHYL)PHOSPHONIC ACID
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonate
(S)-(3-(4-Amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-HPMPC
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonate
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-AMINO-2-OXO-1(2H)-PYRIMIDINYL)-1-(HYDROXYMETHYL)ETHOXY]METHYL]PHOSPHONIC ACID
1-((3-Hydroxy-2-phosphonylmethoxy)propyl)cytosine
1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
|
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
CDV
Cidofovir
Cidofovir anhydrous
Cidofovir sodium
Cidofovir, (+-)-isomer
Cidofovir, (R)-isomer
Cidofovir, sodium salt
CIDOFOVIRUM
GS-0504
HPMPC
Vistide
|
|
31 |
|
Panitumumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
339177-26-3 |
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
32 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
33 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1, Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
34 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
35 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
36 |
|
Edetate calcium disodium anhydrous |
Approved, Vet_approved |
Phase 2 |
|
62-33-9, 60-00-4 |
6049 |
Synonyms:
(Ethylenedinitrilo)tetraacetate, ion(4-)
(ethylenedinitrilo)tetraacetic acid, ion(4−)
(Ethylenedinitrilo)tetraacetic acid, ion(4-)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetate
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetIC ACID
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
Acid, edetic
Acid, ethylenediaminetetraacetic
Acid, ethylenedinitrilotetraacetic
Acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcioedetato de sodio
Calcitetracemate, disodium
Calcium disodium edetate
Calcium disodium edetic acid
Calcium disodium edta
Calcium disodium ethylenediamine tetraacetate
Calcium disodium ethylenediamine tetraacetic acid
Calcium disodium ethylenediaminetetraacetate
Calcium disodium ethylenediaminetetraacetic acid
Calcium disodium versenate
Calcium disodium versenic acid
Calcium edetate de sodium
CALCIUM EDETATE SODIUM
Calcium edetic acid de sodium
Calcium edta
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate (1/2/1)
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid (1/2/1)
CALCIUM SODIUM EDETATE HYDRATE
Calcium sodium edta
Calcium tetacine
CaNa2Edta
Chelaton 3
Chromium edta
Copper edta
Coprin
Dicobalt edta
Dinitrilotetraacetate, disodium ethylene
Dinitrilotetraacetate, ethylene
Disodium calcitetracemate
Disodium calcium edta
Disodium calcium ethylenediaminetetraacetate
Disodium calcium ethylenediaminetetraacetic acid
Disodium edta
Disodium ethylene dinitrilotetraacetate
Disodium monocalcium edta
Disodium versenate, calcium
Distannous edta
E385
Edathamil
Edetate
Edetate calcium
Edetate calcium disodium
Edetate calcium disodium (anhydrous)
Edetate disodium calcium
Edetate, calcium disodium
Edetates
|
Edetic acid
Edetic acid calcium disodium
Edetic acid calcium disodium (anhydrous)
Edetic acid calcium disodium salt
Edetic acid, calcium salt
Edetic acid, calcium, sodium salt
Edetic acid, chromium salt
Edetic acid, dipotassium salt
Edetic acid, disodium salt
Edetic acid, disodium salt, dihydrate
Edetic acid, disodium, magnesium salt
Edetic acid, disodium, monopotassium salt
Edetic acid, magnesium salt
Edetic acid, monopotassium salt
Edetic acid, monosodium salt
Edetic acid, potassium salt
Edetic acid, sodium salt
EDT
EDTA
EDTA CALCIUM DISODIUM
EDTA calcium disodium salt
EDTA disodium calcium salt
EDTA, calcium derivative, disodium salt
EDTA, chromium
EDTA, copper
EDTA, dicobalt
EDTA, disodium
EDTA, distannous
EDTA, gallium
EDTA, ion(4-)
EDTA, magnesium disodium
EDTA, potassium
EDTA, stannous
EDTHAMIL
Ethylene dinitrilotetraacetate
Ethylene dinitrilotetraacetate, disodium
Ethylenediaminetetraacetate
Ethylenediaminetetraacetate calcium disodium salt
Ethylenediaminetetraacetic acid
Ethylenediaminetetraacetic acid calcium disodium salt
Ethylenedinitrilotetraacetic acid
Gallium edta
H4EDta
Magnesium disodium edta
Monocalcium disodium edta
N,N'-1,2-ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycine)
Natrii calcii edetas
Potassium edta
Sodium calcium edetate
Sodium calcium edetic acid
SODIUM CALCIUMEDETATE
Stannous edta
Tetacine, calcium
Tetracemate
Versenate
Versenate, calcium disodium
Versene
Versene acid
VERSENE CA
|
|
37 |
|
Pentetic acid |
Approved |
Phase 2 |
|
67-43-6 |
|
Synonyms:
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetate]
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic acid]
1,1,4,7,7-Diethylenetriaminepentaacetate
1,1,4,7,7-Diethylenetriaminepentaacetic acid
Ca-dtpa
CaDTPA
Calcium trisodium pentetate
CaNa-dtpa
Complexon V
DETAPAC
Diethylene triamine pentaacetic acid
Diethylenetriamine pentaacetic acid
Diethylenetriamine-N,N,n',n'',n''-pentaacetate
Diethylenetriamine-N,N,n',n'',n''-pentaacetic acid
Diethylenetriaminepentaacetate
Diethylenetriaminepentaacetic acid
Diethylenetriaminepentacetate
Diethylenetriaminepentacetic acid
DTPA
DTP-A
H5dTpa
Indium dtpa
|
Indium-dtpa
MN-Dtpa
N,N,N',n'',n''-diethylenetriaminepentaacetate
N,N,N',n'',n''-diethylenetriaminepentaacetic acid
N,N-Bis[2-[bis(carboxymethyl)amino]ethyl]glycine
NSC-7340
Pentaacetic acid, diethylenetriamine
Pentacarboxymethyldiethylenetriamine
Pentacin
Pentacine
Pentaind
Pentetate
Pentetate calcium trisodium
Pentetate zinc trisodium
Pentetate, calcium trisodium
Pentetates
PENTETIC ACID
Penthanil
sn-DTPA
Titriplex V
Zinc dtpa
Zinc-dtpa
|
|
38 |
|
Valproic acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
39 |
|
Avelumab |
Approved, Investigational |
Phase 2 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
40 |
|
Niraparib |
Approved, Investigational |
Phase 1, Phase 2 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
41 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
42 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
43 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
44 |
|
Pomalidomide |
Approved |
Phase 2 |
|
19171-19-8 |
134780 |
Synonyms:
3-aminio-phthalimido-Glutarimide
3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide
3-Aminophthalimidoglutarimide
4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
4-Aminothalidomide
CC 4047
CC-4047
CC-4047|IMID-3|Imnovid®|Pomalyst®
|
IMID-3
IMNOVID
Pomalidomida
POMALIDOMIDE
Pomalyst
S-3-amino-phthalimido-Glutarimide
S-3APG
|
|
45 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
46 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
47 |
|
Palonosetron |
Approved, Investigational |
Phase 2 |
|
119904-90-4, 135729-56-5 |
148211 6337614 |
Synonyms:
(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
2-QHBIQO
Aloxi
Aloxi®|aurothioglucose|RS-25259-197
AUROTHIOGLUCOSE
Onicit
PALONOSETRON
|
Palonosetrón
Palonosétron
Palonosetron hydrochloride
Palonosetron, (R-(r*,r*))-isomer
Palonosetron, (R-(r*,s*))-isomer
Palonosetron, (S-(r*,s*))-isomer
Palonosetronum
|
|
48 |
|
Manganese |
Approved, Nutraceutical |
Phase 1, Phase 2 |
|
7439-96-5 |
27854 |
Synonyms:
MANGANESE (II) ion
Manganese(II)
Manganese, ion (MN2+)
Manganous ion
|
|
|
49 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
50 |
|
Entinostat |
Investigational |
Phase 1, Phase 2 |
|
209783-80-2 |
4261 |
Synonyms:
BAY 86-5274
BAY 86-5274|MS-275|SNDX-275|ZK 244894
BAY86-5274
ENTINOSTAT
Entinostatum
MS 27-275
MS 275
MS-27-275
|
MS-275
MS-275-27
N-(2-Aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamate 3-pyridinylmethyl ester
N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
SNDX 275
SNDX-275
SNDX-275MS-275SID29217590
|
|
Interventional clinical trials:
(show top 50)
(show all 213)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy |
Unknown status |
NCT02369939 |
Phase 3 |
Mitomycin C;5-Fluorouracil |
2 |
Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer |
Completed |
NCT00025090 |
Phase 3 |
cisplatin;fluorouracil;mitomycin C |
3 |
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women |
Completed |
NCT01651949 |
Phase 3 |
|
4 |
Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study |
Completed |
NCT00003652 |
Phase 3 |
cisplatin;fluorouracil |
5 |
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal |
Completed |
NCT00003596 |
Phase 3 |
cisplatin;fluorouracil;mitomycin C |
6 |
A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer |
Completed |
NCT00075868 |
Phase 3 |
octreotide acetate |
7 |
A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults |
Completed |
NCT01164722 |
Phase 3 |
|
8 |
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Na�ve Metastatic Anal Cancer Patients |
Recruiting |
NCT04444921 |
Phase 3 |
Carboplatin;Paclitaxel |
9 |
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors |
Recruiting |
NCT04157985 |
Phase 3 |
Continue PD-1/PD-L1 Inhibitors treatment |
10 |
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma |
Recruiting |
NCT05374252 |
Phase 3 |
PD-1 inhibitor |
11 |
Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery |
Recruiting |
NCT02997553 |
Phase 3 |
Indocyanine green;Technetium99 |
12 |
Dietary Fiber During Radiotherapy and Intestinal Inflammation - a Placebo-controlled Randomized Trial (FIDURA) |
Recruiting |
NCT04534075 |
Phase 3 |
|
13 |
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer |
Active, not recruiting |
NCT03233711 |
Phase 3 |
|
14 |
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study |
Active, not recruiting |
NCT02135419 |
Phase 3 |
imiquimod;fluorouracil |
15 |
A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. |
Active, not recruiting |
NCT04635423 |
Phase 3 |
|
16 |
Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer |
Enrolling by invitation |
NCT02526953 |
Phase 3 |
Paclitaxel;Capecitabine;Mitomycins |
17 |
Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study |
Terminated |
NCT00068744 |
Phase 2, Phase 3 |
cisplatin;fluorouracil;mitomycin C |
18 |
An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease |
Unknown status |
NCT02051868 |
Phase 2 |
Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel |
19 |
Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer |
Unknown status |
NCT03381352 |
Phase 2 |
Capecitabine;Mitomycin C |
20 |
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand |
Unknown status |
NCT03302858 |
Phase 2 |
|
21 |
Randomized Phase 2 Trial of Cetuximab and Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment |
Unknown status |
NCT03944252 |
Phase 2 |
Avelumab;Cetuximab |
22 |
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Prospective, Phase II Trial Assessing Acute Toxicities Rates Compared to Historic Controls Treated With Volumetric Modulated Arc Therapy (VMAT) |
Completed |
NCT03690921 |
Phase 2 |
Cisplatin;Fluorouracil |
23 |
A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal |
Completed |
NCT00423293 |
Phase 2 |
fluorouracil;mitomycin C |
24 |
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers |
Completed |
NCT02280811 |
Phase 1, Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
25 |
Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women |
Completed |
NCT00550589 |
Phase 2 |
cidofovir |
26 |
A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal |
Completed |
NCT00093379 |
Phase 2 |
Capecitabine;Oxaliplatin |
27 |
A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals |
Completed |
NCT00052897 |
Phase 1, Phase 2 |
|
28 |
Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal |
Completed |
NCT02399813 |
Phase 2 |
ADXS11-001 |
29 |
Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma |
Completed |
NCT00324415 |
Phase 2 |
cisplatin;fluorouracil |
30 |
Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma |
Completed |
NCT00316888 |
Phase 2 |
cisplatin;fluorouracil |
31 |
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers |
Completed |
NCT01585428 |
Phase 2 |
Fludarabine;Cyclophosphamide;Aldesleukin |
32 |
AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males |
Completed |
NCT01209325 |
Phase 2 |
|
33 |
A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men |
Completed |
NCT00428285 |
Phase 2 |
|
34 |
Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream |
Completed |
NCT00622440 |
Phase 2 |
AIJP (Arnebia Indigo Jade Pearl);Placebo |
35 |
Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging |
Completed |
NCT01717391 |
Phase 2 |
fluorothymidine F 18 |
36 |
Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma. |
Completed |
NCT02402842 |
Phase 2 |
Docetaxel, Cisplatin and 5-Fluorouracil |
37 |
Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus |
Completed |
NCT01581840 |
Phase 1, Phase 2 |
radiochemotherapy;Panitumumab |
38 |
A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2 |
Completed |
NCT03499795 |
Phase 2 |
|
39 |
Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma |
Completed |
NCT01285778 |
Phase 2 |
panitumumab, mytomicin C, 5-FU, radiation |
40 |
Risk-Adapted Therapy for HIV-Associated Anal Cancer |
Recruiting |
NCT04929028 |
Phase 2 |
Capecitabine;Fluorouracil;Mitomycin |
41 |
Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes |
Recruiting |
NCT04907643 |
Phase 2 |
|
42 |
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. |
Recruiting |
NCT04230759 |
Phase 2 |
Chemotherapy;Durvalumab |
43 |
ReRad III. Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy |
Recruiting |
NCT05055635 |
Phase 2 |
|
44 |
A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) |
Recruiting |
NCT04166318 |
Phase 2 |
Capecitabine;Fluorouracil;Mitomycin |
45 |
A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001 |
Recruiting |
NCT03386500 |
Phase 1, Phase 2 |
BMX-001 |
46 |
ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer |
Recruiting |
NCT05438836 |
Phase 2 |
|
47 |
A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) |
Recruiting |
NCT03870607 |
Phase 2 |
|
48 |
Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies |
Recruiting |
NCT04287868 |
Phase 1, Phase 2 |
|
49 |
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
Recruiting |
NCT04708470 |
Phase 1, Phase 2 |
Bintrafusp Alfa;NHS-IL12;Entinostat |
50 |
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) |
Recruiting |
NCT02628067 |
Phase 2 |
|
|